CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.

Area of Science:

• Pharmacology
• Neuroscience
• Toxicology

Background:

• Emergency room visits for cannabinoid toxicity are rising, driven by potent synthetic cannabinoids.
• Unlike opioid overdoses, there is no specific antidote for cannabinoid toxicity.
• Current treatments for cannabinoid toxicity include supportive care or sedatives, which have risks.

Purpose of the Study:

• To investigate the potential of CB1 receptor negative allosteric modulators (NAMs) as an antidote for synthetic cannabinoid toxicity.
• To evaluate the efficacy of specific CB1 NAMs (ABD1085, RTICBM189, PSNCBAM1) in reversing the effects of JWH018, a potent synthetic cannabinoid.

Main Methods:

• In vitro testing on autaptic hippocampal neurons to assess the reversal of JWH018 effects on endogenous cannabinoid signaling.
• In vivo testing in mice using a nociception assay to evaluate the blockade of JWH018 effects.
• Assessment of PSNCBAM1 for its ability to reverse JWH018 effects when administered post-exposure and its effect on withdrawal symptoms after chronic JWH018 treatment.

Main Results:

• All tested CB1 NAMs (ABD1085, RTICBM189, PSNCBAM1) reversed JWH018 effects in vitro, with varying potency.
• In vivo, only RTICBM189 and PSNCBAM1 blocked JWH018 effects when administered preventatively; in vitro potency did not predict in vivo efficacy.
• PSNCBAM1 demonstrated higher potency in vivo, reversed JWH018 effects post-administration, and did not induce withdrawal after chronic JWH018 exposure.

Conclusions:

• CB1 NAMs can effectively reverse the toxic effects of the synthetic cannabinoid JWH018 both in vitro and in vivo.
• PSNCBAM1 shows particular promise as a potential antidote for synthetic cannabinoid toxicity due to its potency and lack of withdrawal induction.
• These findings suggest a novel pharmacological strategy for managing cannabinoid toxicity.